Boston Scientific Corp
I · Analyse IA
En bref
Boston Scientific designs and sells specialized medical equipment that doctors use during minimally-invasive procedures — think catheters, stents, implants, and electronic devices that treat conditions in the heart, digestive tract, urinary system, and nervous system [Boston Scientific]. Their products help cardiologists open blocked arteries, urologists treat bladder problems, and pain specialists manage chronic pain through implanted nerve stimulators [Boston Scientific].
Boston Scientific is a $84.4 billion medical device company that makes products for heart procedures, digestive system treatments, urology, and pain management [Yahoo Finance]. The company reported strong revenue growth of 19.9% year-over-year and recently announced a $2 billion share buyback alongside a $1.5 billion investment in MiRus, a company developing a new heart valve technology [Yahoo Finance]. Recent clinical trial success with its SEISMIQ 4CE device for treating severely calcified heart arteries positions the company well in a challenging cardiac niche [Simply Wall St].
Boston Scientific is financially stable with strong cash generation, though debt levels are moderate and returns on invested capital remain below 10% [Yahoo Finance].
Score Sentinellis
6.3/10
Moderate concerns
Capitalisation boursière
$84.4B
Chiffre d'affaires (12 mois)
$20.1B
II · Actualités récentes
Ce qui a fait bouger le cours
6 stories · ranked by relevance
- macro2026-05-20
Boston Scientific Trial Success Adds Weight To SEISMIQ 4CE And BSX Valuation
Simply Wall St
- macro2026-05-20
Boston Scientific Corporation (BSX) Fell Due to Weak Results
Yahoo Finance
- macro2026-05-20
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target
Yahoo Finance
- macro2026-05-19
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?
Yahoo Finance
- macro2026-05-19
FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Yahoo Finance
- macro2026-05-18
Boston Scientific announces strategic investment in MiRus LLC
Yahoo Finance
Premium · gratuit avec tout compte
The company's stock underperformed in Q1 2026 as part of broader market weakness driven by geopolitical conflicts, private credit concerns, government shutdown, and AI uncertainty, with Boston Scientific being among top holdings in funds that lost over 11% during the period [Yahoo Finance].
Risques
4
Opportunités
6
Direction
10
19 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Boston Scientific Corp
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 4 risques et 6 opportunités — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
- Export PDF pour la lecture hors ligne
III · Entreprises similaires
À lire également
Same sector · Healthcare or comparable health
L'ajouter à votre liste ?